ClinicalTrials.gg
Not yet recruitingNCT06864507Updated Mar 7, 2025

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.

A Phase 1/2 interventional study of HS-10561 and Placebo in Chronic Spontaneous Urticaria, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.

Planned enrollment
12th of 30
150 · median 110
Started
2025
with 4 others
Phase 1/2
4 of 34
4 open now
Primary completion
2026-09
later than 4 of 19 live
Registered
18th of 34
by date

Among the 34 studies in Chronic Urticaria with a site in China, this one is the 12th largest by planned enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 4 of the 19 other live ones, and was the 18th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Chronic Urticaria with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HS-10561 capsule in healthy Chinese adults and patients with chronic spontaneous urticaria.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • Chronic spontaneous urticaria
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed.(SD)
  • Healthy adults aged 18-45 years (inclusive) at the time of signing the informed consent form;(SD)
  • Male participants weighing ≥ 50 kg and female participants weighing ≥ 40 kg; (weight/square of height (kg/m2)) within the range of 18-30 kg/m2 (inclusive);(SD)
  • Female participants and male participants (including their female partners) agree to use highly effective methods of from the date of signing the informed consent form until 30 days after the last dose;(SD)
  • Without history of severe respiratory, gastrointestinal (such as inflammatory bowel disease, Crohn's disease, chronic diarrhea, etc.), neurological, circulatory, urinary, endocrine, musculoskeletal, immune system disorders, or a history of tumors prior to screening.(SD)
  • Written informed consent must be obtained before any assessment is performed.(MD and Phase 2)
  • Healthy adults aged 18-65 years (inclusive) at the time of signing the informed consent form;(MD and Phase 2)
  • Have been diagnosed with chronic spontaneous urticaria for ≥6 months at the time of screening;(MD and Phase 2)
  • Female participants and male participants (including their female partners) agree to use highly effective methods of contraception from the date of signing the informed consent form until 30 days after the last dose.(MD and Phase 2)

Exclusion criteria

Exclusion Criteria:

  • Have abnormalities in vital signs, physical examination, laboratory tests, chest X-ray/CT, or abdominal ultrasound during the screening period, which, as assessed by the investigator, may increase the participants' risk or affect the scientific validity of the study;(SD)
  • Females with a positive blood pregnancy test, breastfeeding females, or participants planning to become pregnant during the study period;(SD)
  • Any physiological or psychological condition or disease, as determined by the investigator, that could increase the risk, affect the participants' compliance, or impact the participants' ability to complete the study.(SD)
  • Chronic urticaria with a clear primary or sole trigger (chronic inducible urticaria);(MD and Phase 2)
  • Clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria);(MD and Phase 2)
  • Other diseases with symptoms of urticaria or angioedema;(MD and Phase 2)
  • Other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results;(MD and Phase 2)
  • Pregnant or nursing (lactating) women.(MD and Phase 2)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    HS-10561 Dose 1

    HS-10561, Dose 1

    Drug: HS-10561

  • Experimental
    HS-10561 Dose 2

    HS-10561, Dose 2

    Drug: HS-10561

  • Experimental
    HS-10561 Dose 3

    HS-10561, Dose 3

    Drug: HS-10561

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Single and multiple doses of HS-10561 orally

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation.(Phase 1)

    Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation.

    Time frame: SD:up to 7 days,MD:up to 35 days

  2. Change from baseline in Weekly Urticaria Activity Score (UAS7) at Week 4 (Phase 2)

    The Weekly Urticaria Activity Score (UAS7) is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42 (highest urticaria severity), and a minimum possible score of 0.

    Time frame: Week 4

Secondary outcomes

  1. Cmax

    Maximum plasma concentration

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

  2. Tmax

    Time to reach Cmax

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

  3. AUC

    Area under the plasma concentration-time curve

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

  4. t½

    Terminal half-life

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

  5. CL/F

    Apparent clearance

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

  6. Vd/F

    Apparent volume of distribution

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

  7. Rac

    Accumulation ratio

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

  8. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation.(Phase 2)

    Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation;Clinically significant changes in physical examination and anamnesis, vital signs, ECG, safety laboratory will be reported under (S)AEs.

    Time frame: up to 16 weeks

  9. Change from baseline in Weekly Itch Severity Score (ISS7) at Week 12(Phase 2)

    The severity of the itch was recorded by the participant daily in their electronic Diary, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest itch severity).

    Time frame: Week 12

  10. Change from baseline in Weekly Hives Severity Score (HSS7) at Week 12(Phase 2)

    The hives (wheals) severity score, defined by number of hives, was recorded by the participant daily in their electronic Diary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly score (HSS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest hives activity).

    Time frame: Week 12

07

Study locations

1 site
  • Shanghai Hospital of Skin Disease
    Shanghai, Shanghai 201203, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Sep 2026, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 7, 2025
StartEst.
Mar 31, 2025
Primary completionEst.
Sep 27, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06864507
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Mar 31, 2025 (estimated)
Primary completion
Sep 27, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocbrutinib

Start the discussion